4-2016-0678 for the 16 NSCLC patients undergoing anti-PD-1 treatment and IRB no

4-2016-0678 for the 16 NSCLC patients undergoing anti-PD-1 treatment and IRB no

4-2016-0678 for the 16 NSCLC patients undergoing anti-PD-1 treatment and IRB no. in cancer. Finally, the level in the TI T cells was found to be highly predictive of overall survival and anti-PD-1 efficacy in melanoma and NSCLC. Conclusions We predicted the regulatory factors involved